REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX - Get Free Report) will be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.24. The firm had revenue of $22.30 million for the quarter, compared to analysts' expectations of $22.97 million. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.66) earnings per share. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

REGENXBIO Trading Down 2.8 %

Shares of REGENXBIO stock traded down $0.25 during trading on Thursday, hitting $8.59. The stock had a trading volume of 499,571 shares, compared to its average volume of 592,528. The firm has a market cap of $423.11 million, a price-to-earnings ratio of -1.51 and a beta of 1.21. REGENXBIO has a 12 month low of $8.56 and a 12 month high of $28.80. The business's 50-day moving average is $10.92 and its 200 day moving average is $12.81.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Barclays reduced their target price on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating on the stock in a research note on Monday, August 5th. HC Wainwright restated a "buy" rating and set a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Tuesday, October 22nd. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Finally, Raymond James restated an "outperform" rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.45.

Insider Activity at REGENXBIO

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at approximately $130,466.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 13.13% of the stock is owned by corporate insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.